Skip to main content

Repare Therapeutics Inc.

RPTXDelisted Jan 28, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001808158

Repare Therapeutics Inc. was delisted on Jan 28, 2026; its insiders filed their last Form 4 on Jan 30, 2026; 46 institutions reported holding it in 13F filings for Q4 2025, worth $65.4M in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
46
Q4 2025, +2 vs. previous quarter
13F value
$65.4M
Reported value at the end of Q4 2025
Superinvestors holding
0
At the end of Q4 2025

From SEC filings, in USD.

Revenue, FY2024
–
No comparable prior period
Net income, FY2024
-$84.7M
No comparable prior period
Free cash flow, FY2024
-$76.4M
No comparable prior period
Revenue, Q3 FY2025
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Jan 15, 2026.

Short interest
437.9K
Shares sold short
Change
+243.6K
+125.3% vs. previous
Days to cover
1.00
At average daily volume

Superinvestors holding RPTX, Q4 2025

Go to the superinvestors tab

No superinvestor reported holding RPTX at the end of Q4 2025.

Latest insider trades

See all insider trades

Open-market purchases and sales by Repare Therapeutics Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 14, 2025 (view filing)Mar 122 daysKoehler MariaEVP, CHIEF MEDICAL OFFICERSSale−3.60K$1.14−$4.10K−1.6%227.8K after
Mar 14, 2025 (view filing)Mar 122 daysZinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSSale−5.61K$1.14−$6.40K−6.5%80.3K after
Mar 14, 2025 (view filing)Mar 122 daysForte SteveEVP, CHIEF FINANCIAL OFFICERSSale−6.88K$1.14−$7.85K−11.2%54.8K after
Mar 14, 2025 (view filing)Mar 122 daysSegal Lloyd MitchellPRESIDENT AND CEOSSale−21.2K$1.14−$24.1K−14.5%124.4K after
Apr 1, 2024 (view filing)Mar 28-Apr 14 daysSegal Lloyd MitchellPRESIDENT AND CEOSSale−5.14K$4.62−$23.8K−4.6%107.6K after2 lots10b5-1
Apr 1, 2024 (view filing)Mar 28-Apr 14 daysForte SteveEVP, CHIEF FINANCIAL OFFICERSSale−1.61K$4.62−$7.45K−3.5%44.8K after2 lots10b5-1
Apr 1, 2024 (view filing)Mar 28-Apr 14 daysZinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSSale−860$4.65−$4.00K−1.2%71.9K after2 lots10b5-1
Apr 1, 2024 (view filing)Mar 28-Apr 14 daysKoehler MariaEVP, CHIEF MEDICAL OFFICERSSale−800$4.65−$3.72K−0.3%231.4K after2 lots10b5-1
Mar 27, 2024 (view filing)Mar 25-272 daysForte SteveEVP, CHIEF FINANCIAL OFFICERSSale−2.48K$4.67−$11.6K−5.5%42.2K after3 lots10b5-1
Mar 27, 2024 (view filing)Mar 25-272 daysZinda MichaelEVP, CHIEF SCIENTIFIC OFFICERSSale−1.35K$4.67−$6.30K−1.8%72.8K after3 lots10b5-1

Top 10 13F holders, Q4 2025

See all 46 holders

The largest institutional positions in Repare Therapeutics Inc. at the end of Q4 2025; share changes are against Q3 2025.

Institutions holding RPTX in Q4 2025
InstitutionSharesValue% of portfolioChange in sharesAction
BVF Inc10,333,600$26.9M0.90%00.0%Unchanged
Blue Owl Capital Holdings LP3,443,659$8.95M2.76%00.0%Unchanged
OrbiMed Advisors LLC3,322,488$8.64M0.18%00.0%Unchanged
Redmile Group, LLC1,586,174$4.12M0.30%00.0%Unchanged
Rangeley Capital, LLC1,287,829$3.35M2.88%+641,953+99.4%Added
Marshall Wace, LLP1,115,744$2.90M0.00%+1,115,744New
Renaissance Technologies LLC981,360$2.55M0.00%+257,200+35.5%Added
Acadian Asset Management LLC618,672$1.61M0.00%+50,371+8.9%Added
Two Sigma Investments, LP333,694$867.6K0.00%+322,727+2,942.7%Added
Jane Street Group, LLC278,304$723.6K0.00%+278,304New

Holders of 5% or more of RPTX

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Repare Therapeutics Inc..

Largest holders of RPTX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Shay Capital LLC13G6.70%2.87M sharesNewJan 27, 20261 filingJan 27, 2026SEC